Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.38 |
| ▸ | SRC | P12931 | 8/20 | 0.37 |
| ▸ | KDR | P35968 | 7/20 | 0.37 |
| ▸ | CSK | P41240 | 3/20 | 0.35 |
| ▸ | TEK | Q02763 | 3/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KIF5B | P33176 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485512 | 0.93 | EGFR (0.39) | EGFRERBB2SRCKDRERBB4 | |
| SCHEMBL13485492 | 0.88 | EGFR (0.41) | EGFRERBB2SRCKDRCSK | |
| SCHEMBL13485435 | 0.87 | KDR (0.46) | EGFRERBB2SRCKDRCSK | |
| SCHEMBL13485489 | 0.83 | EGFR (0.41) | EGFRERBB2SRCKDRCSK | |
| SCHEMBL13485434 | 0.82 | SRC (0.44) | EGFRERBB2SRCKDRCSK | |
| SCHEMBL13485493 | 0.80 | EGFR (0.42) | EGFRERBB2SRCKDRERBB4 | |
| SCHEMBL13485436 | 0.79 | SRC (0.43) | EGFRSRCKDRCSKTEK | |
| SCHEMBL13485510 | 0.73 | CCR6 (0.35) | — | |
| SCHEMBL13485509 | 0.73 | CCR6 (0.34) | — | |
| SCHEMBL13500131 | 0.68 | SRC (0.47) | EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044084-B1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-8492377-B2 | MTKI quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-23 | — | — | US | disclosed |
| US-8492377-B2 | MTKI quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-04 | — | — | US | disclosed |
| WO-2008006884-A2 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | NR4A3, NR4A1, NR5A2 | EGFR 1555/4885ERBB2 754/4885SRC 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.